Amylyx Pharmaceuticals

Amylyx Pharmaceuticals, Inc. operates as a biopharmaceutical company, which provides disease-modifying solutions for neurodegenerative diseases. The firm focuses on streamlined clinical development and drug discovery. It specializes in developing a proprietary therapeutic for Amyotrophic Lateral Sclerosis (ALS) and other neurodegenerative diseases that target the neuroinflammation and nerve cell death that characterize these disorders. The company was founded by Joshua Cohen and Justin Klee in 2013 and is headquartered in Cambridge, MA.

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Amylyx Pharmaceuticals excels in Q4 with RELYVRIO launch success

Amylyx Pharmaceuticals demonstrated strong financial performance in Q4 2022, driven by the successful commercial launch of RELYVRIO for ALS treatment.
The company's focus on key priorities for the U.S. launch and commitment to serving ALS patients position it well for future growth and impact.
While facing challenges in meeting analyst expectations and study success criteria, Amylyx Pharmaceuticals remains optimistic about the opportunities ahead in advancing ALS treatment.

Amylyx Pharmaceuticals achieves profitability in Q1, plans global PSP study

Amylyx Pharmaceuticals delivered strong financial performance in Q1, driven by the success of RELYVRIO and plans for AMX0035 in PSP. While facing challenges in profitability expectations and pipeline expansion, the company is well-positioned to capitalize on opportunities for growth and impact.

Amylyx Pharmaceuticals reports robust Q2 performance and strategic growth focus

Amylyx Pharmaceuticals' Q2 2023 Earnings Call highlighted strong financials, patient-centric initiatives, and advancements in R&D programs for neurodegenerative diseases.
Analysts' inquiries underscored the need for clarity on compliance rates, expansion strategies, and study design considerations to address potential challenges.
The company's emphasis on trial design strength, patient support, and market positioning opportunities signals a strategic focus on growth and innovation.

Amylyx Pharmaceuticals reports strong Q3 earnings, eyes growth opportunities

Amylyx Pharmaceuticals had a strong Q3 performance with significant net product revenues and a focus on expanding patient reach. While facing challenges in discontinuations and revenue impact, the company is optimistic about growth opportunities through education and trial results.

Amylyx Pharmaceuticals reports robust earnings, poised for market expansion

Amylyx Pharmaceuticals had a successful year financially, with strong revenue growth and a solid financial position.
The company's focus on expanding market reach, developing innovative biomarkers, and enhancing disease diagnosis underscores their commitment to advancing ALS treatment.
While facing uncertainties with upcoming trial data and regulatory challenges, Amylyx remains optimistic about growth opportunities and R&D advancements.

Amylyx Pharmaceuticals adapts strategy post-PHOENIX trial, eyes regulatory milestones

Amylyx Pharmaceuticals navigated a challenging quarter with a focus on pipeline diversification and strategic planning for multiple neurodegenerative diseases. Despite setbacks in the PHOENIX trial, the company remains resilient and proactive in addressing challenges while seizing opportunities for growth and regulatory progress.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Amylyx Pharmaceuticals, Inc. is a commercial-stage biotechnology company, which engages in the provision of therapies for neurodegenerative diseases and amyotrophic lateral sclerosis (ALS). Its commercial product is Relyvrio, also known as Albrioza in Canada. The company was founded by Joshua Cohen and Justin Klee in 2013 and is headquartered in Cambridge, MA.

Alpha Metallurgical Resources

Axsome Therapeutics

CONSOL Energy

Crescent Point Energy

Digi

Enphase Energy

First Solar

Golar LNG

International Seaways

Kellogg

Occidental Petroleum

Super Micro Computer

Semtech

Scorpio Tankers

Sierra Wireless

Transmedics Group Inc

Historic 2022 inflation lifted energy and value stocks while sinking growth plays. The post 100 Best Stocks Of 2022: Fossil Fuel Ignites, Solar Shines, Meds Make Miracles appeared first on Investor's Business Daily.

100 Best Stocks Of 2022: Fossil Fuel Ignites, Solar Shines, Meds Make Miracles

Amylyx Pharmaceuticals, Inc. received a surprise approval for Relyvrio in ALS. The approval is great for the once-small company.

Amylyx: Future Looks Good After Surprise Approval, But Unpredictable, Too

CAMBRIDGE, Mass.--( BUSINESS WIRE )--Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) today announced that Joshua Cohen and Justin Klee, Co-CEOs of Amylyx, will participate in the Evercore ISI 5th Annual HealthCONx Conference. The conference is being conducted in a virtual format, and the fireside chat will take place on Tuesday, November 29, 2022 at 3:05 p.m. ET.

Amylyx Pharmaceuticals to Participate in the Evercore ISI 5th Annual HealthCONx Conference

Arcellx

Belite Bio Inc

CinCor Pharma

Credo Technology Group Holding Ltd

Golden Sun Education Group Ltd

AMTD Digital

Mobileye Global Inc

Nuvectis Pharma

The IPO market has been slow this year as investors' risk appetite for new issues hit a record low.

These Are the 10 Best-Performing IPOs in 2022 Through October

Biogen

The neuroscience renaissance is here. Biotech stocks are soaring this year on expectations for new treatments in brain-health disorders.

Biotech Stocks Embrace The Neuroscience Renaissance With Biogen, Amylyx At The Helm

Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX ) Q3 2022 Earnings Conference Call November 10, 2022 4:30 PM ET Company Participants Lindsey Allen - Head of Investor Relations and Communications Justin Klee - Co-Chief Executive Officer Margaret Olinger - Chief Commercial Officer James Frates - Chief Financial Officer Josh Cohen - Co-Chief Executive Officer Conference Call Participants Corinne Jenkins - Goldman Sachs Michael DiFiore - Evercore Inc. Marc Goodman - SVB Securities Neena Bitritto-Garg - Citigroup Inc. Ananda Ghosh - H.C. Wainwright & Co. Operator Good afternoon.

Amylyx Pharmaceuticals, Inc. (AMLX) Q3 2022 Earnings Call Transcript

CAMBRIDGE, Mass.--( BUSINESS WIRE )--Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) (“Amylyx” or the “Company”) today reported financial results for the quarter ended September 30, 2022.

Amylyx Pharmaceuticals Reports Third Quarter 2022 Financial Results

Amylyx Pharmaceuticals to Report Third Quarter 2022 Financial Results on November 10, 2022

NeuroSense Therapeutics Ltd

View the Nasdaq Opening Bell Ringing & CEO Message Here: LINK CAMBRIDGE, Mass. , Oct. 18, 2022 /PRNewswire/ -- NeuroSense Therapeutics Ltd.

NeuroSense Therapeutics Provides CEO's Q3 Update and Nasdaq Opening Bell Ceremony Remarks Video

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Amylyx Pharmaceuticals, Inc. (“Amylyx”) today announced the closing of its previously announced upsized underwritten public offering of 7,697,812 shares of its common stock at a public offering price of $32.00 per share, which includes the exercise in full by the underwriters of their option to purchase up to an additional 1,004,062 shares of common stock in the offering. The gross proceeds to Amylyx from the offering were $246.3 million, before deducting unde

Amylyx Pharmaceuticals Announces Closing of Upsized Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Amylyx Pharmaceuticals Announces Pricing of Upsized Public Offering of Common Stock.

Amylyx Pharmaceuticals Announces Pricing of Upsized Public Offering of Common Stock

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Amylyx Pharmaceuticals Announces Launch of Public Offering.

Amylyx Pharmaceuticals Announces Launch of Public Offering

Amylyx Pharmaceuticals Inc.'s AMLX, -1.13% new treatment for amyotrophic lateral sclerosis just received approval in the U.S., but it's already facing questions about effectiveness and price.

FDA approves new ALS drug that costs $158,000 a year

Amylyx (AMLX) obtains the FDA's approval for its oral, fixed-dose combination therapy for treating adults with amyotrophic lateral sclerosis (ALS) after a few roadblocks.

Amylyx (AMLX) Secures the FDA's Approval for ALS Drug

Relvyrio, Amylyx's drug to treat ALS, a neurological disorder without a cure, was approved even though the treatment is very expensive.

Amylyx Shows FDA Can Be Flexible on Drugs for Diseases With Few Treatments

Shares of Amylyx Pharmaceuticals (NASDAQ: AMLX ) stock were up as much as 10% in premarket trading today on news that the U.S. Food and Drug Administration (FDA) has approved its treatment of the deadly disease amyotrophic lateral sclerosis (ALS). The approval marks the first time the FDA has greenlit a new ALS treatment in five years and represents a breakthrough for Amylyx Pharma.

AMLX Stock Alert: Amylyx Pharma Gains on Huge FDA Win

Amylyx Pharmaceuticals Inc said on Friday it has set the list price of its newly approved drug to slow the progression of amyotrophic lateral sclerosis (ALS) at about $158,000 per year in the United States.

Amylyx prices newly approved ALS drug at $158,000 per year

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Amylyx Pharmaceuticals Announces FDA Approval of RELYVRIO™ for the Treatment of ALS in Adults.

Amylyx Pharmaceuticals Announces FDA Approval of RELYVRIO™ for the Treatment of ALS

After a long road, Amylyx Pharmaceuticals won FDA approval for its ALS treatment late Thursday, leading AMLX stock to surge. The post IPO Scorcher Amylyx Wins FDA Approval In ALS Treatment, Ending A Long Battle appeared first on Investor's Business Daily.

IPO Scorcher Amylyx Wins FDA Approval In ALS Treatment, Ending A Long Battle

The drug is the first that the Food and Drug Administration has approved for ALS, also known as Lou Gehrig's disease, in five years.

Amylyx's ALS Drug Is Approved by the FDA

WASHINGTON — A much-debated drug for Lou Gehrig's disease won U.S. approval Thursday, a long-sought victory for patients that is likely to renew questions about the scientific rigor behind government reviews of experimental medicines.

Amylyx's ALS drug wins FDA approval despite questionable data

The U.S. Food and Drug Administration on Thursday approved Amylyx Pharmaceuticals Inc's drug for slowing progression of ALS, or amyotrophic lateral sclerosis, and potentially delaying death.

U.S. FDA approves Amylyx ALS drug

DocGo

HilleVax Inc

This down market is giving us some really intriguing stocks at cheap prices.

3 IPO Stocks That You Want to Own

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Amylyx announced that the donated clinical data from the placebo arm of the CENTAUR clinical trial are now available in the PRO-ACT database.

Amylyx Pharmaceuticals Announces Donated CENTAUR Clinical Trial Data Now Available to Help Advance Science in ALS for Future Treatments and Discoveries

The experimental treatment was recently backed by an FDA advisory committee

News for Amylyx Pharmaceuticals Stock (AMLX)